June 04, 2010 06:00 PM Eastern Daylight Time

Data from Combination of REVLIMID® and Rituxan® in Untreated Indolent B-Cell Non-Hodgkin’s Lymphoma Presented at ASCO

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ:CELG) today announced that initial data from an investigator-initiated study of REVLIMID (lenalidomide) plus Rituxan (rituximab) in patients with newly diagnosed indolent B-cell non-Hodgkin’s lymphoma (NHL) were presented at the annual...

admin

MAY 21, 2010
By JENNIFER CORBETT DOOREN And RON WINSLOW

New uses for two established cancer drugs significantly increased the time patients survived without their disease progressing, in studies that provide fresh evidence of how cancer is often becoming a chronic disease.

Researchers said Rituxan, co-marketed in the U.S. by Roche Holding AG's Genentech unit and Biogen Idec Inc., cut the risk of cancer returning in certain lymphoma patients by half when used as a...

admin

Risk of relapse reduced 50 percent after 2 yrs

*Cancer progressed in 18 pct of Rituxan patients

Thu May 20, 2010 1:35pm EDT
By Deena Beasley

LOS ANGELES, May 20 (Reuters) - Continued use of Rituxan, a drug sold by Roche Holding AG (ROG.VX) and Biogen Idec Inc (BIIB.O), reduced by about 50 percent the chance that follicular lymphoma patients would have their cancer return, according to a late-stage study.

Last year Rituxan, known outside the...

admin

May 13, 2010 5:16 a.m. EST

AHN News Staff

Toronto, Ontario, Canada (AHN) - Ontario joined on Wednesday other Canadian provinces in agreeing to pay for a new leukemia drug. Ontario’s decision leaves Nova Scotia as the only holdout among the provinces.

The medication to be funded by the provinces is Rituximab. A spokesman of the Ontario Health Ministry said the province’s Committee to Evaluate Drugs recommended the inclusion of the medication for blood and bone-marrow...

admin

Research and Markets: Threats to Avastin - Targeting the Vascular Endothelial Growth Factor Pathway

May 12, 2010 08:00 AM Eastern Daylight Time

DUBLIN--(BUSINESS WIRE)--Research and Markets (Threats to Avastin - Targeting the VEGF Pathway - Market Research Reports - Research and Markets) has announced the addition of the "Threats to Avastin - Targeting the VEGF Pathway" report to their offering.

Avastin is set to become the most successful cancer...

admin